logo

Intraday Alerts

Share SHARE

Cubic Corp. (CUB) gapped open higher Friday morning and has continued to rise in early trade. Shares are now up 3.15 at $49.95. Cubic Corp. has been gaining ground for the past 3 weeks and has climbed to a 4 1/2 month high. The stock has re-crossed its 200-day moving average.

CarMax Inc. (KMX) reported second quarter EPS of $0.98 Friday morning, up from $0.84 in the prior year period. Analysts expected EPS of $0.95. CarMax gapped open higher Friday and is now up 3.56 at $72.40. The stock has broken out of a 2 1/2 week trading range and has set a new high for the year.

Madrigal Pharmaceuticals Inc. (MDGL) gapped up at the open Friday and has risen sharply in early trade. The stock is now up 5.37 at $27.70 on above average volume. Madrigal Pharmaceuticals has been on an upward trend for the past 2 weeks and has surged to a new high for the year.

Versartis Inc. (VSAR) announced after the close Thursday that its Phase 3 study of somavaratan did not meet its primary endpoint. Versartis has gapped open dramatically lower Friday morning and is now down 18.53 at $3.08 on the highest volume of the year. The stock has plunged to a new low for the year.

Ascendis Pharma (ASND) has gapped open sharply higher Friday morning and is now up 11.85 at $39.59 on above average volume. The stock has jumped to a new high for the year. Ascendis Pharma announced Thursday that it will present on its rare disease dndocrinology pipeline at the upcoming American Society...

Akari Therapeutics (AKTX) announced Thursday morning that it plans to advance Coversin towards Phase III clinical studies in the first quarter of 2018. The decision was made following a recent Type B End of Phase II Meeting with the FDA. Akari Therapeutics gapped up at the open Thursday and has since...

Scholastic Corp. (SCHL) reported a first quarter loss of $1.81 per share Thursday morning, compared to last year's loss of $1.15 per share. Revenue in the first quarter was $189.2 million, down 33 percent from $282.7 million a year ago. Scholastic gapped open sharply lower this morning and is now...

Matson Inc. (MATX) gapped up at the open Thursday and has spiked higher in early trade. The stock is currently higher by 3.02 at $29.37. Matson has broken out to a 1-month high and has re-crossed its 50-day moving average.

Anadarko Petroleum (APC) announced after the close Wednesday that its board of directors has authorized a $2.5 billion share-repurchase program. Anadarko Petroleum gapped open sharply higher Thursday morning and is now up 2.85 at $47.66. The stock has jumped to nearly a 2-month high.

Calgon Carbon Corp. (CCC) announced Thursday morning that it has agreed to be acquired by Kuraray for $21.50 per share in cash. Calgon Carbon has gapped open dramatically higher this morning and is now up 8.13 at $21.33 on the highest volume of the year. The stock has soared to a new high for the year.

Roper Technologies Inc. (ROP) gapped open higher Wednesday morning and has continued to rise in early trade. Shares are now up 6.50 at $245.10. Roper Technologies has broken out past resistance Wednesday and has set a new high for the year.

BEST Inc. (BSTI) has just begun trading for the first time Wednesday morning. The company prices its initial public offering of 45,000,000 ADS at US$10.00 per ADS. BEST is now up 1.30 at $11.30 on nearly 4 million shares.

General Mills (GIS) reported first quarter EPS of $0.71 Wednesday morning, down from $0.78 in the prior year period. Street expectations were for EPS of $0.76. Net sales declined 4 percent to $3.77 billion. Analysts expected revenue of $3.79 billion. General Mills gapped open sharply lower this morning...

Bed Bath & Beyond (BBBY) reported second quarter EPS of $0.67 after the bell Tuesday, down from $1.11 in the previous year. Analysts expected EPS of $0.95. Bed Bath & Beyond has gapped open sharply lower Wednesday morning and is now down 4.34 at $22.69. The stock has dropped below over a 1-month trading...

Alnylam Pharmaceuticals Inc. (ALNY) and Sanofi Genzyme announced Wednesday morning that their Phase 3 study of patisiran, in patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary endpoint and all secondary endpoints. Alnylam Pharmaceuticals has gapped open dramatically higher...

Follow RTT